At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer care. 

We are thankful to be part of the HER2+ breast cancer community and are passionate about evaluating options that may benefit patients across the breast cancer therapy spectrum.

Puma Biotechnology, Inc.

Seagen is a biotechnology company focused on developing and commercializing innovative cancer therapies.

Seagen

Genentech is a leading biotechnology company known for its pioneering work in developing biologic therapies for various diseases, including cancer.

Genentech

Novartis is a global pharmaceutical company with a diverse portfolio of innovative medicines, including treatments for cancer and other complex diseases.

Novartis

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral) for early stage HER2-overexpressed/amplified breast cancer, neratinib in combination with capecitabine for advanced or metastatic HER2-positive breast cancer, and for HER2 mutation-positive solid tumors. Its products also include PB272 (neratinib, intravenous), and PB357.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 28, 2024 4:01 AM	e4b6fb19
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 28, 2024 4:01 AM	ae945a80
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Feb 28, 2024 4:01 AM	26a350bf
translate crunchbase fundingrounds	general
peers	general
news basic	general	Feb 28, 2024 4:01 AM	f3547e58
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:PUMABIOTECHNOLOGY

Puma Biotechnology, Inc.

Last Close

2.90

22/11 21:00

Market Cap

146.65M

Beta: -

Volume Today

536.92K

Avg: -